Non-Invasive Hemodynamic Monitoring for Pulmonary Embolism
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to explore how non-invasive blood pressure monitors can help manage pulmonary embolism (PE), a serious condition where blood clots block the blood vessels in the lungs. Researchers will focus on measuring and monitoring stroke volume (the amount of blood pumped by the heart with each beat) to observe changes during treatment. This could improve understanding of how the heart copes with PE and help predict patient outcomes more accurately. Suitable candidates for this trial include those diagnosed with PE who require intensive care. As an unphased trial, this study offers patients the opportunity to contribute to groundbreaking research that could enhance future PE treatments.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this non-invasive hemodynamic monitoring is safe for patients with pulmonary embolism?
Research has shown that non-invasive methods to monitor blood flow and heart function are safe in many medical settings. These methods use devices like finger cuffs to assess heart function without surgery or needles. Studies have found that these non-invasive monitors provide real-time information about heart health, which is crucial for individuals with conditions like blood clots in the lungs.
This non-invasive approach is generally easy for patients to handle and carries a low risk of side effects. These monitors are often considered safer than traditional methods involving surgery or needles. While research has not reported specific side effects for this type of monitoring, the non-invasive nature itself reduces the likelihood of complications. This should reassure participants about the safety of joining a trial that uses non-invasive heart monitoring.12345Why are researchers excited about this trial?
Researchers are excited about non-invasive hemodynamic monitoring for pulmonary embolism because it offers a way to assess heart and lung function without the need for invasive procedures. Traditional treatments for pulmonary embolism often involve anticoagulant medications and, in severe cases, surgical interventions like catheter-directed thrombolysis. This new method provides critical information about blood flow and pressure in real-time, potentially helping doctors make quicker and more accurate treatment decisions. By eliminating the need for invasive techniques, this approach could reduce patient risk and improve recovery times.
What evidence suggests that non-invasive hemodynamic monitoring is effective for pulmonary embolism?
Research has shown that non-invasive methods to measure heart function can greatly improve care for patients with a pulmonary embolism (PE). In this trial, participants will undergo non-invasive hemodynamic monitoring to track stroke volume, the amount of blood the heart pumps with each beat, in real-time. Studies indicate that monitoring stroke volume helps doctors predict and manage heart issues during a PE. Non-invasive techniques, such as using finger cuffs with sensors, allow for continuous monitoring without surgery or other invasive procedures. Early research suggests this approach could lead to better outcomes by detecting heart problems early and allowing for quick treatment adjustments.23467
Who Is on the Research Team?
Richard Channick, MD
Principal Investigator
University of California, Los Angeles
Are You a Good Fit for This Trial?
This trial is for adults over 18 in intensive care with confirmed pulmonary embolism (PE) who can sign a consent form. It's not for those under 120 cm tall, on ECMO, with BMI <20 or >35, atrial fibrillation, certain heart valve issues, scleroderma, or end-stage renal disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients with confirmed PE are monitored using non-invasive hemodynamic measurement devices for 12 to 24 hours
Follow-up
Participants are monitored for safety and effectiveness after treatment through their hospitalization
What Are the Treatments Tested in This Trial?
Interventions
- Non-invasive hemodynamic measurements
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor